Vertex to Buy Crinetics for 10 Billion Dollars in Cash as Biotech Deal-Making Accelerates
Vertex Pharmaceuticals agreed to buy Crinetics Pharmaceuticals for about 10 billion dollars in cash at a 102 percent premium, expanding into endocrinology as biotech mergers accelerate in 2026.